Latest Headlines

Latest Headlines

Eagle Pharma files for $50 million IPO

The Woodcliff Lake, NJ-based company tweaks existing injectable drugs to make them preferable to the original therapies and says it is working on 6 advanced development programs with two approved products.

Cancer drug Treanda gets orphan status, but that won't save Teva's shrinking profits

Teva Pharmaceutical Industries hasn't had much good news to share lately. Today, it had a little something to crow about: The FDA has granted orphan status to its cancer-fighting drug, Treanda.

Whistleblower says Cephalon ignored DoJ pact to push off-label uses

The allegations in a recently released lawsuit against Cephalon suggest that company was particularly obscene about pushing off-label uses, because at the time it was operating under a Corporate Integrity Agreement forged after getting caught for similar problems a few years earlier.

Study of Treanda shows great promise for Teva's drug

Boosted by an intriguing backstory tied to the Cold War, a study showing Teva Pharmaceutical's Treanda worked better on patients with non-Hodgkin lymphomas and produced fewer side effects, is getting lots of attention at ASCO.

Lundbeck banks on pipeline as antidepressant sales skid

Lundbeck's CFO Anders Gotzsche emphasized the prospects of drugs such as Selincro for alcohol dependence, the experimental antidepressant Lu AA21004 in late-stage development and a long-lasting formulation of Abilify.

Teva's Cephalon recalls leukemia drug over fragments in vial

Teva Pharmaceutical Industries' ($TEVA) Cephalon has recalled one lot of leukemia drug Treanda after glass fragments were found in one of the vials. FDA-approved labeling for Treanda states that...

Feds probe Cephalon on Provigil, Nuvigil promos

The Justice Department isn't just interested in Cephalon's Treanda operations. It's also looking at the drugmaker's wakefulness meds Nuvigil and Provigil. Cephalon ($CEPH) said the feds issued a

Feds cite HIPAA in subpoena on Cephalon's Treanda

Cephalon has received another query from the feds. As Pharmalot reports, the company disclosed a subpoena from the U.S. Attorney's Office in New York, requesting information about the company's

Feds probe Cephalon's Treanda marketing

Yet another drugmaker finds itself under the U.S. Justice Department microscope. As Pharmalot reports, Cephalon ($CEPH) has received some requests from the feds for documents relating to potential

Treanda data could lead to 10-fold sales jump

Cephalon could have a blockbuster on its hands following the release of new data about its tumor-fighting therapy Treanda. The drug is currently approved for a form of non-Hodgkin lymphoma, which